Optimizing Healthcare Outcomes: Clinical Advancements, Economic Impact of RYONCIL in Treating Pediatric SR-aGVHD

May 1, 2025

Overview

Thursday, May 1, 2025 at 2-3pm ET                             Pricing: Free for Members and Non-Members

Please note that this session is not accredited for continuing pharmacy education credit.

Program Description

Join us for an insightful webinar on the advancements in treating pediatric steroid-refractory acute versus host disease (SR-aGVHD) with RYONCIL®, which was approved by the FDA on December 19, 2024. Dr. McSweeney will delve into the significant unmet need in SR-aGVHD, a condition with high morbidity and mortality rates, and how Ryoncil’s safety and efficacy offers a promising new therapeutic option that has significant impact on long-term survival outcomes.

He will present the clinical challenges, economic burden, and the next-generation immune modulation properties of mesenchymal stem cells that make RYONCIL® a valuable addition to pediatric care.

Ms. Wehling will cover the economic value of RYONCIL®, highlighting its potential to deliver significant healthcare cost savings due to substantial long-term survival benefits, utilizing health economic models for ultra-rare diseases and high-impact therapies.

Learning Objectives

  • Understand the significant unmet need in treating pediatric steroid-refractory acute graft-versus-host disease (SR-aGVHD) and the clinical challenges associated with this high-risk condition.
  • Understand the unique mechanism of action, safety, and efficacy of RYONCIL®, and how these contribute to survival outcomes in pediatric SR-aGVHD.
  • Explore the economic impact associated with the use of RYONCIL® in treating pediatric SR-aGVHD.

This webinar is sponsored, developed, and presented by the sponsor. The content of this Science & Innovation Webinar and opinions expressed by the presenters are those of the sponsor or presenters and not of AMCP.

Sponsored by:

For individuals from the media/press interested in attending, please email media@amcp.org.

Course summary
Course opens: 
03/25/2025
Course expires: 
05/01/2025
Event starts: 
05/01/2025 - 2:00pm EDT
Event ends: 
05/01/2025 - 3:00pm EDT
Cost:
$0.00
Add to calendar: 

Faculty

Speakers:

Peter McSweeney, MB ChB
Head of Medical Affairs
Mesoblast

Dr. Peter McSweeney is the Head of Medical Affairs at Mesoblast, with a wealth of experience in hematologic malignancies. He trained in internal medicine, hematology, and hematopathology in New Zealand before joining Fred Hutchinson Cancer Research Center, where he was ana attending physician and performed laboratory and clinical research from 1989 to 1999. During his tenure, he developed pioneering clinical studies and protocols for transplants in hematologic malignancies and autoimmune diseases.

Dr. McSweeney continued his academic career at the University of Colorado from 1999 to 2003, as the Director of the  Allogeneic Hematopoietic Transplant Program. He then transitioned to the Colorado Blood Cancer Institute, where he held leadership roles in research, clinical programs, and practice management from 2004 to 2022.

Dr. McSweeney has been an investigator in numerous clinical trials, including allogeneic transplants for hematologic malignancies, autoimmune diseases, and CAR T cell therapy. His extensive expertise includes leukemia, lymphoma, and myeloma, with a focus on allogeneic and autologous transplantation for these diseases.


Jodie Wehling
Vice President Market Access
Mesoblast

Jodie Wehling leads the Market Access function at  Mesoblast and is responsible for developing and executing the market access strategies, pricing, trade & distribution, and patient support plans for RYONCIL®.

Previously, Jodie held leadership roles at CARGO Therapeutics, Atara Bio, Celgene and Johnson & Johnson. She has extensive experience in patient access, managing reimbursement, and developing payer, provider, and patient engagement strategies. Jodie is recognized for her expertise in cell & gene therapy, rare diseases, oncology, and developing health economic model strategies.

Register/Take course

Price

Cost:
$0.00
Please login or register to take this course.

Required Hardware/software

AMCP Learn utilizes the Zoom Webinars platform for live webinars. For a smoother experience joining the webinar, please install the Zoom desktop client or mobile app prior to the start time. If you experience technical issues joining the webinar, please email webinars@amcp.org.